نيوزتري
دخولإنشاء حساب
القصص/

TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)

مشاركة:

TimesSquare Capital Management, an equity investment management company, released its "U.S. Mid Cap Growth Strategy" first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside temporary global tariffs. High oil prices and supply chain disruptions followed U.S. and Israeli involvement in Iran, prompting a shift to safer assets and a reevaluation of supply chains and energy dependencies. Central banks maintained steady policies despite energy-driven inflation. In this environment, the Strategy remains focused on disciplined management teams with durable competitive advantages. Please review the Strategy's top five holdings to gain insights into their key selections for 2026. In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN). Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On June 30, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $18.07 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was -2.48%, and its shares lost 26.18% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of about $4.93 billion. TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q1 2026 investor letter: "Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. Stevanato Group S.p.A. (NYSE:STVN) supplies drug containment, drug delivery, and diagnostic solutions to the biopharmaceutical industry. Its shares declined by -32% on market concerns that the shift to oral GLP1 drug formulations could slow growth in injectable products. However, we believe these concerns may be overblown as Stevanato has several multi-year contracts representing strong revenue visibility. " Is Stevanato Group S.p.A. (STVN) the Best Italian Stock to Buy in 2025? Stevanato Group S.p.A. (NYSE:STVN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 21 hedge fund portfolios held Stevanato Group S.p.A. (NYSE:STVN) at the end of the first quarter, up from 15 in the previous quarter. While we acknowledge the potential of Stevanato Group S.p.A. (NYSE:STVN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

📰آخر التطورات(1 أخبار)

●

TimesSquare Mid Cap Growth Strategy Downplays Market Fears on Stevanato Group S.p.A. (STVN)

ياهو فاينانس|١‏/٧‏/٢٠٢٦|70%

TimesSquare Capital Management, an equity investment management company, released its "U.S. Mid Cap Growth Strategy" first-quarter 2026 investor letter. A copy of the letter can be downloaded here. The Strategy fell 7.72% (net) in the quarter compared to -6.35% for the Russell Midcap Growth Index. In the first quarter, markets navigated geopolitical tensions and economic resilience alongside temporary global tariffs. High oil prices and supply chain disruptions followed U.S. and Israeli involvement in Iran, prompting a shift to safer assets and a reevaluation of supply chains and energy dependencies. Central banks maintained steady policies despite energy-driven inflation. In this environment, the Strategy remains focused on disciplined management teams with durable competitive advantages. Please review the Strategy's top five holdings to gain insights into their key selections for 2026. In its first-quarter 2026 investor letter, TimesSquare Capital U.S. Mid Cap Growth Strategy highlighted Stevanato Group S.p.A. (NYSE:STVN). Stevanato Group S.p.A. (NYSE:STVN) is an Italian company that designs and distributes products and processes that offer integrated solutions for the biopharma and healthcare industries. On June 30, 2026, Stevanato Group S.p.A. (NYSE:STVN) closed at $18.07 per share. One-month return of Stevanato Group S.p.A. (NYSE:STVN) was -2.48%, and its shares lost 26.18% over the past 52 weeks. Stevanato Group S.p.A. (NYSE:STVN) has a market capitalization of about $4.93 billion. TimesSquare Capital U.S. Mid Cap Growth Strategy stated the following regarding Stevanato Group S.p.A. (NYSE:STVN) in its Q1 2026 investor letter: "Our preferences among Health Care stocks are those companies providing novel therapies for unmet needs that command premium pricing, or specialized service providers. Stevanato Group S.p.A. (NYSE:STVN) supplies drug containment, drug delivery, and diagnostic solutions to the biopharmaceutical industry. Its shares declined by -32% on market concerns that the shift to oral GLP1 drug formulations could slow growth in injectable products. However, we believe these concerns may be overblown as Stevanato has several multi-year contracts representing strong revenue visibility. " Is Stevanato Group S.p.A. (STVN) the Best Italian Stock to Buy in 2025? Stevanato Group S.p.A. (NYSE:STVN) is not on our list of 40 Most Popular Stocks Among Hedge Funds Heading Into 2026. According to our database, 21 hedge fund portfolios held Stevanato Group S.p.A. (NYSE:STVN) at the end of the first quarter, up from 15 in the previous quarter. While we acknowledge the potential of Stevanato Group S.p.A. (NYSE:STVN) as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.